Real-world treatment patterns and outcomes in patients initiating lurasidone for the treatment of schizophrenia in Europe
Introduction Lurasidone is a second-generation antipsychotic shown to have a lower risk of weight gain and a lower incidence of metabolic adverse events compared with some medications in the same class. Objectives To describe treatment patterns, clinical outcomes and adverse drug reactions (ADRs)...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2022-06-01
|
| Series: | European Psychiatry |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822005375/type/journal_article |